永昕生醫 and Alfresa Holdings have established a joint venture to create a biopharmaceutical production base in Japan, marking a significant step towards international growth for 永昕.

Target Information

永昕生醫 recently announced a strategic partnership with Alfresa Holdings Corporation, a leader in the Japanese pharmaceutical distribution sector, along with two other Japanese pharmaceutical companies. They will be establishing a joint venture named Alfenax Biologic Corporation, aimed at creating a biopharmaceutical production base in Japan. This collaboration represents 永昕's official entry into the domestic biopharmaceutical manufacturing landscape in Japan and marks a significant milestone in their transition from a regional Contract Development and Manufacturing Organization (CDMO) to an international biopharmaceutical manufacturing partner.

Alfresa Holdings is recognized as the foremost group among the four major prescription drug distribution entities in Japan, boasting annual revenues exceeding ¥3 trillion (approximately NT$600 billion). This positioning allows the company to actively seek integration opportunities across various stages of the supply chain, thereby enhancing its competitive edge and expanding its growth avenues.

Industry Overview in Japan

The pharmaceutical industry in Japan is characterized by high concentration and fierce competition. The government's recent initiatives to localize biopharmaceutical production are being propelled by the dual pressures of healthcare finance and